339 results on '"Vekeman, Francis"'
Search Results
52. MP286NATURAL HISTORY FOR ADULT PATIENTS WITH SPORADIC ANGIOMYOLIPOMA IN THE NETHERLANDS
53. A Life-Course Assessment of Treatment Patterns and Healthcare Costs of Lennox-Gastaut Syndrome (LGS) (P1.085)
54. Tu1905 Assessment of the Real-World Safety Profile of Vedolizumab Using the United States Food and Drug Administration Adverse Event Reporting System (FAERS)
55. Epidemiologic and Clinical Characteristics of Thalassemia (Thal) Intermedia (TI) in the United States
56. Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia
57. Age-Related Emergency Department Reliance in Patients with Sickle Cell Disease
58. Patient and Caregiver Burden Associated With Fragile X Syndrome in the United States
59. Kidney involvement in tuberous sclerosis complex: the impact on healthcare resource use and costs
60. Costs, resource utilization, and treatment patterns for patients with metastatic melanoma in a commercially insured setting
61. Treatment patterns and characteristics of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus.
62. Clinical features and overall survival (OS) in patients (pts) with post-docetaxel (DTX) metastatic castration-resistant prostate cancer (mCRPC) receiving second-line (2L) therapy in the community setting.
63. Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer (mCRC) treated with ziv-aflibercept (Z) in community oncology practices in the United States (US).
64. Response to Comment on “Is Addition of Vasodilators to Loop Diuretics of Value in the Care of Hospitalized Acute Heart Failure Patients? Real-World Evidence From a Retrospective Analysis of a Large United States Hospital Database”
65. Development of a claims-based classifier to identify Lennox-Gastaut Syndrome (P7.030)
66. Medical complications, resource utilization and costs in patients with myelofibrosis by frequency of blood transfusion and iron chelation therapy
67. Multicenter COMPACT study of COMplications in Patients with sickle cell disease And utilization of iron Chelation Therapy
68. Adherence to Iron Chelation Therapy and Associated Healthcare Resource Utilization and Costs in Medicaid Patients with Sickle Cell Disease
69. Economic burden of brain metastases among patients with metastatic melanoma in a USA managed care population
70. Pulse pressure and stroke risk: development and validation of a new stroke risk model
71. Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first‐line sunitinib: a medical chart review across ten centers in five European countries
72. Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia
73. High Resource Utilizers From The Multicenter Compact Study Of Complications In Patients With Sickle Cell Disease and Utilization Of Iron Chelation Therapy
74. Transition From Pediatric To Adult Care Of High Cost Patients In a Medicaid Population With Sickle Cell Disease
75. Medical Complications In Patients With Myelofibrosis By Frequency Of Blood Transfusion and Iron Chelation Therapy
76. Age-Related Emergency Department Reliance and Healthcare Resource Utilization in Patients with Sickle Cell Disease
77. Final Results From the Multicenter Compact Study of Complications in Patients with Sickle Cell Disease and Utilization of Iron Chelation Therapy: A Retrospective Medical Records Review.
78. ARE VASODILATORS OF ANY VALUE IN THE CARE OF HOSPITALIZED ACUTE HEART FAILURE PATIENTS?
79. Lifetime costs to Medicare of providing care to patients with chronic lymphocytic leukemia
80. Utilization and cost comparison of erythropoiesis-stimulating agents in inpatient and outpatient hospital settings
81. Age-Related Blood Transfusion Patterns in Patients with Sickle Cell Disease (SCD) and the Association with Sickle Cell Complications
82. Age-Related Iron Chelation Utilization and Healthcare Costs in Patients with Sickle Cell Disease (SCD)
83. Epidemiologic Evaluation of Cardiovascular Risk in Patients Receiving Milnacipran, Venlafaxine, or Amitriptyline: Evidence from French Health Data
84. Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population
85. Healthcare costs associated with nephrology care in pre-dialysis chronic kidney disease patients
86. Tolerability, Efficacy, and Safety of Pegylated Liposomal Doxorubicin in Combination with Carboplatin Versus Gemcitabine–Carboplatin for the Treatment of Platinum‐Sensitive Recurrent Ovarian Cancer: A Systematic Review
87. Drug Utilization and Cost for Erythropoiesis-Stimulating Agents in a Long-Term Care Resident Population with Chronic Kidney Disease
88. 39: Epoetin Alfa Dosing Trend Over Time in Adult Patients With Chronic Kidney Disease: A Medical Benefit Perspective
89. 37: Dosing Trends Over Time of Epoetin Alfa Utilization in Chronic Kidney Disease Patients Not on Dialysis:APharmacy Benefit Perspective
90. Comment: The Impact of Methodological Approach on Cost Findings in Comparison of Epoetin Alfa with Darbepoetin Alfa
91. Persistence and Compliance of Deferoxamine Versus Deferasirox in Medicaid Patients with Sickle-Cell Disease.
92. Costs to Medicare of Treating Chronic Lymphocytic Leukemia Patients with Alemtuzumab.
93. P2-227: Compliance, persistence, and outcomes in patients with Alzheimer's disease treated with oral cholinesterase inhibitors
94. Direct All-Cause Health Care Costs Associated With Chronic Kidney Disease in Patients With Diabetes and Hypertension: A Managed Care Perspective
95. Drug utilisation and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database
96. Comparison of Infection-Related Hospitalization Risk and Associated Costs among Patients Receiving Sargramostim (Leukine®), Filgrastim (Neupogen®), and Pegfilgrastim (Neulasta®) for Chemotherapy-Induced Neutropenia
97. Comparison of Epoetin Alfa and Darbepoetin Alfa Dosing and Costs in an Inpatient Population with Myelodysplastic Syndromes
98. Higher Erythroid Response Rates with Epoetin Alfa Versus Other Agents in Treatment-Naïve Low/Int-1 Myelodysplastic Syndrome Patients: A Comparative Meta-Analysis
99. P4-308: Antipsychotic drug use in patients with Alzheimer's disease treated with Rivastigmine versus donepezil: Evidence from health claims data
100. 130: Drug Utilization and Cost Considerations of Predialysis Chronic Kidney Disease Patients Receiving Erythropoietic Stimulating Agents Through Pharmacy Benefits
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.